• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Churchill Capital Corp XI

    2/17/26 8:31:38 AM ET
    $CCXI
    Get the next $CCXI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Churchill Capital Corp XI

    (Name of Issuer)


    Class A ordinary shares, par value $0.0001

    (Title of Class of Securities)


    G2131A124

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G2131A124


    1Names of Reporting Persons

    MAGNETAR FINANCIAL LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,700,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,700,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,700,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.44 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP No.
    G2131A124


    1Names of Reporting Persons

    MAGNETAR CAPITAL PARTNERS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,700,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,700,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,700,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.44 %
    12Type of Reporting Person (See Instructions)

    HC, PN


    SCHEDULE 13G

    CUSIP No.
    G2131A124


    1Names of Reporting Persons

    SUPERNOVA MANAGEMENT LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,700,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,700,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,700,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.44 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    G2131A124


    1Names of Reporting Persons

    DAVID J. SNYDERMAN
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,700,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,700,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,700,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.44 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Churchill Capital Corp XI
    (b)Address of issuer's principal executive offices:

    640 Fifth Avenue, 12th Floor, New York, NY 10019
    Item 2. 
    (a)Name of person filing:

    This statement is filed on behalf of each of the following person (collectively, the "Reporting Persons"): i) Magnetar Financial LLC ("Magnetar Financial"); ii) Magnetar Capital Partners LP ("Magnetar Capital Partners"); iii) Supernova Management LLC ("Supernova Management"); and iv) David J. Snyderman ("Mr. Snyderman"). This statement relates to the Shares (as defined herein) held for Magnetar Constellation Master Fund, Ltd ("Constellation Master Fund"), Magnetar Xing He Master Fund Ltd ("Xing He Master Fund"), Magnetar Capital Master Fund Ltd ("Capital Master Fund"), all Cayman Islands exempted companies; Magnetar Structured Credit Fund, LP ("Structured Credit Fund"), a Delaware limited partnership; Magnetar Alpha Star Fund LLC ("Alpha Star Fund"), Magnetar Lake Credit Fund LLC ("Lake Credit Fund"), Purpose Alternative Credit Fund - T LLC ("Purpose Credit Fund - T"), and Magnetar Waterfront Series A LLC ("Waterfront Series A") all Delaware limited liability companies; collectively (the "Magnetar Funds"). Magnetar Financial serves as the investment adviser to the Magnetar Funds, and as such, Magnetar Financial exercises voting and investment power over the Shares held for the Magnetar Funds' accounts. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Financial. Supernova Management is the general partner of Magnetar Capital Partners. The administrative manager of Supernova Management is Mr. Snyderman.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of Magnetar Financial, Magnetar Capital Partners, Supernova Management, and Mr. Snyderman is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201.
    (c)Citizenship:

    Place of Organization. i) Magnetar Financial is a Delaware limited liability company; ii) Magnetar Capital Partners is a Delaware limited partnership; iii) Supernova Management is a Delaware limited liability company; and iv) Mr. Snyderman is a citizen of the United States of America.
    (d)Title of class of securities:

    Class A ordinary shares, par value $0.0001
    (e)CUSIP No.:

    G2131A124
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of December 31, 2025, each of Magnetar Financial, Magnetar Capital Partners, Supernova Management and Mr. Snyderman held 2,700,000 Shares. The amount consists of (A) 675,000 Shares held for the account of Constellation Master Fund; (B) 459,000 Shares held for the account of Lake Credit Fund; (C) 540,000 Shares held for the account of Structured Credit Fund; (D) 405,000 Shares held for the account of Xing He Master Fund; (E) 459,000 Shares held for the account of Alpha Star Fund; (F) 54,000 Shares held for the account of Purpose Credit Fund - T; (G) 27,000 shares held for the account of Capital Master Fund; and (H) 81,000 Shares held for the account Waterfront Series A. The Shares held by the Magnetar Funds represent approximately 6.44% of the total number of Shares outstanding (calculated pursuant to Rule 13d-3(d)(1)(i)) of the outstanding shares of the Issuer).
    (b)Percent of class:

    As of December 31, 2025, each of the Reporting Persons were deemed to be the beneficial owner constituting approximately 6.44% of the total number of shares outstanding (based upon the information provided provided by the Issuer in the Form 8-K filed on December 18, 2025 there are approximately 41,900,000 Shares outstanding).
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    2,700,000

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    2,700,000

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    MAGNETAR FINANCIAL LLC
     
    Signature:/s/ Hayley Stein
    Name/Title:Name: Hayley Stein, Title: Attorney-in-fact for David J. Snyderman, Administrative Manager of Supernova Management LLC
    Date:02/17/2026
     
    MAGNETAR CAPITAL PARTNERS LP
     
    Signature:/s/ Hayley Stein
    Name/Title:Name: Hayley Stein, Title: Attorney-in-fact for David J. Snyderman, Administrative Manager of Supernova Management LLC
    Date:02/17/2026
     
    SUPERNOVA MANAGEMENT LLC
     
    Signature:/s/ Hayley Stein
    Name/Title:Name: Hayley Stein, Title: Attorney-in-fact for David J. Snyderman, Administrative Manager of Supernova Management LLC
    Date:02/17/2026
     
    DAVID J. SNYDERMAN
     
    Signature:/s/ Hayley Stein
    Name/Title:Name: Hayley Stein, Title: Attorney-in-fact for David J. Snyderman, Administrative Manager of Supernova Management LLC
    Date:02/17/2026

    Comments accompanying signature:  MAGNETAR FINANCIAL LLC BY: Magnetar Capital Partners LP, its Sole Member BY: Supernova Management LLC, its General Partner MAGNETAR CAPITAL PARTNERS LP By: Supernova Management LLC, its General Partner
    Exhibit Information

    99.1 Joint Filing Agreement, dated as of February 17, 2026, among the Reporting Persons. 99.2 Power of Attorney, dated as of December 22, 2022 filed by the Reporting Persons on February 17, 2026.

    Get the next $CCXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCXI

    DatePrice TargetRatingAnalyst
    8/4/2022$81.00Buy
    Canaccord Genuity
    11/10/2021$107.00 → $110.00Strong Buy
    Raymond James
    10/11/2021$14.00 → $38.00Underweight → Neutral
    JP Morgan
    10/11/2021$64.00Mkt Perform → Outperform
    SVB Leerink
    10/11/2021$62.00 → $107.00Outperform → Strong Buy
    Raymond James
    10/8/2021$62.00 → $107.00Outperform → Strong Buy
    Raymond James
    10/8/2021Neutral → Overweight
    Piper Sandler
    7/7/2021$26.00 → $31.00Hold → Buy
    Stifel
    More analyst ratings

    $CCXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Klein Michael Stuart bought $5,000,000 worth of Class A Ordinary Shares (500,000 units at $10.00) (SEC Form 4)

    4 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/19/25 5:16:36 PM ET
    $CCXI

    $CCXI
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Churchill Capital Corp XI

    SCHEDULE 13G - Churchill Capital Corp XI (0002074973) (Subject)

    2/17/26 4:00:12 PM ET
    $CCXI

    SEC Form SCHEDULE 13G filed by Churchill Capital Corp XI

    SCHEDULE 13G - Churchill Capital Corp XI (0002074973) (Subject)

    2/17/26 3:10:21 PM ET
    $CCXI

    SEC Form SCHEDULE 13G filed by Churchill Capital Corp XI

    SCHEDULE 13G - Churchill Capital Corp XI (0002074973) (Subject)

    2/17/26 8:31:38 AM ET
    $CCXI

    $CCXI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for TAVNEOS issued to CHEMOCENTRYX, INC.

    Submission status for CHEMOCENTRYX, INC.'s drug TAVNEOS (ORIG-1) with active ingredient AVACOPAN has changed to 'Approval' on 10/07/2021. Application Category: NDA, Application Number: 214487, Application Classification: Type 1 - New Molecular Entity

    10/15/21 3:42:50 PM ET
    $CCXI

    $CCXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Klein Michael Stuart bought $5,000,000 worth of Class A Ordinary Shares (500,000 units at $10.00) (SEC Form 4)

    4 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/19/25 5:16:36 PM ET
    $CCXI

    SEC Form 3 filed by new insider Klein Michael Stuart

    3 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/16/25 9:40:41 PM ET
    $CCXI

    SEC Form 3 filed by new insider Sherman William M

    3 - Churchill Capital Corp XI (0002074973) (Issuer)

    12/16/25 9:40:10 PM ET
    $CCXI

    $CCXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity resumed coverage on ChemoCentryx with a new price target

    Canaccord Genuity resumed coverage of ChemoCentryx with a rating of Buy and set a new price target of $81.00

    8/4/22 8:51:51 AM ET
    $CCXI

    Raymond James reiterated coverage on ChemoCentryx with a new price target

    Raymond James reiterated coverage of ChemoCentryx with a rating of Strong Buy and set a new price target of $110.00 from $107.00 previously

    11/10/21 9:06:49 AM ET
    $CCXI

    ChemoCentryx upgraded by JP Morgan with a new price target

    JP Morgan upgraded ChemoCentryx from Underweight to Neutral and set a new price target of $38.00 from $14.00 previously

    10/11/21 8:32:48 AM ET
    $CCXI

    $CCXI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Churchill Capital Corp XI Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing February 9, 2026

    New York, NY, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Churchill Capital Corp XI (NASDAQ:CCXIU) (the "Company") announced today that, commencing February 9, 2026, holders of the units sold in the Company's initial public offering may elect to separately trade the Company's Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on the Nasdaq Global Market under the symbols "CCXI" and "CCXIW," respectively. Those units not separated will continue to trade on the Nasdaq Global Market under the symbol "CCXIU." This press re

    2/5/26 4:28:00 PM ET
    $CCXI

    AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

    TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl

    10/20/22 9:05:00 AM ET
    $AMGN
    $CCXI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings

    -- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November. American Society of Nephrology Kidney Week 2022, November 3-6, Orlan

    10/17/22 8:30:00 AM ET
    $CCXI

    $CCXI
    Financials

    Live finance-specific insights

    View All

    AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX

    TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl

    10/20/22 9:05:00 AM ET
    $AMGN
    $CCXI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference Call

    SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022. About ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. 

    8/9/22 8:30:00 AM ET
    $CCXI

    ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022

    SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (International). The conference ID number is 9726781. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast wil

    8/2/22 4:05:00 PM ET
    $CCXI

    $CCXI
    Leadership Updates

    Live Leadership Updates

    View All

    ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent Director

    SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. "With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS® (avacopan) commercial efforts," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Jennifer's values closely align with our organization, and we are confident this addition

    7/5/22 8:30:00 AM ET
    $CCXI

    ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer

    Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug de

    10/11/21 8:30:00 AM ET
    $CCXI

    ChemoCentryx Announces Appointment of Susan M. Kanaya to Board of Directors

    MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021. “Susan Kanaya’s many fundamental contributions have been key to ChemoCentryx’s growth and prosperity,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Over many formative years of our enterprise, she ensured our strong financial position, allowing us to achieve our operational plans and thus increasing shareholder value while serving patients’ needs. As a

    3/8/21 8:30:00 AM ET
    $CCXI

    $CCXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    9/12/22 11:13:14 AM ET
    $CCXI

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    2/9/22 3:33:37 PM ET
    $CCXI

    SEC Form SC 13G/A filed by ChemoCentryx Inc. (Amendment)

    SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)

    2/9/22 9:11:44 AM ET
    $CCXI